Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Research & Development (2015 - 2026)

Updated

Grace Therapeutics (GRCE) reported Research & Development of $885,000 for fiscal Q2 2027 (quarter ended Sep 30, 2026), up 55.8% from $568,000 a year earlier and up 27.0% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Research & Development (2015 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, Grace Therapeutics' Research & Development came in at $2.46 million, down 54.0% year-over-year; for FY2026 (ended Mar 31, 2026), it was $2.41 million, down 74.7% from FY2025.

  • Research & Development has a five-year compound annual growth rate of -10.4% (FY2021 to FY2026).
  • By fiscal year, Research & Development came in at $9.51 million in FY2025 (+103.1%), $4.68 million in FY2024 (-53.0%), $9.97 million in FY2023 (+79.4%) and $5.56 million in FY2022 (+33.2%).
  • The fiscal Q2 2027 figure ranks as the highest quarterly Research & Development since fiscal Q1 2026.
  • Year over year, Research & Development gained in two of the last eight quarters, with an average decline of 27.6%.
  • The high point for year-over-year Research & Development in five years was fiscal Q2 2025 (growth of 547.0%); the low point was fiscal Q2 2024 (a decline of 86.0%).
  • Per Business Quant data, the three fiscal quarters before Q2 2027 came in at $697,000 (Q1 2027), $420,000 (Q4 2026) and $462,000 (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 4.25 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 4.65 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 2.57 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 4.54 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 3.89 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 1.61 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 3.02 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn - 885,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 885,000.00
Jun 30, 2026 697,000.00
Mar 31, 2026 420,000.00
Dec 31, 2025 462,000.00
Sep 30, 2025 568,000.00
Jun 30, 2025 955,000.00
Mar 31, 2025 1.63 Mn
Dec 31, 2024 2.19 Mn
Sep 30, 2024 2.98 Mn
Jun 30, 2024 2.71 Mn
Mar 31, 2024 1.69 Mn
Dec 31, 2023 1.44 Mn
Sep 30, 2023 460,000.00
Jun 30, 2023 1.10 Mn
Mar 31, 2023 1.64 Mn
Dec 31, 2022 2.45 Mn
Sep 30, 2022 3.29 Mn
Jun 30, 2022 2.59 Mn
Mar 31, 2022 2.33 Mn
Dec 31, 2021 2.18 Mn
API Access

Grace Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=GRCE&period=max&api_key=YOUR_API_KEY